FDA approves Amgen drug for small cell lung cancer

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's (AMGN.O) tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung cancer that has worsened despite chemotherapy.